-$0.13 Earnings Per Share Expected for Evogene Ltd (EVGN) This Quarter

Analysts predict that Evogene Ltd (NYSE:EVGN) will announce earnings per share of ($0.13) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Evogene’s earnings. Evogene reported earnings per share of ($0.18) in the same quarter last year, which suggests a positive year over year growth rate of 27.8%. The company is scheduled to issue its next quarterly earnings results on Thursday, August 10th.

According to Zacks, analysts expect that Evogene will report full year earnings of ($0.68) per share for the current financial year. For the next fiscal year, analysts forecast that the business will report earnings of ($0.02) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Evogene.

Evogene (NYSE:EVGN) last issued its quarterly earnings results on Wednesday, May 17th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.01. The company had revenue of $0.72 million during the quarter. Evogene had a negative return on equity of 18.60% and a negative net margin of 235.47%.

COPYRIGHT VIOLATION WARNING: This story was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/2656029/0-13-earnings-per-share-expected-for-evogene-ltd-evgn-this-quarter.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EVGN. JPMorgan Chase & Co. boosted its position in Evogene by 53.4% in the first quarter. JPMorgan Chase & Co. now owns 245,425 shares of the biotechnology company’s stock valued at $4,079,000 after buying an additional 85,425 shares during the last quarter. Vanguard Group Inc. boosted its position in Evogene by 4.2% in the first quarter. Vanguard Group Inc. now owns 418,834 shares of the biotechnology company’s stock valued at $2,240,000 after buying an additional 16,964 shares during the last quarter. UBS Group AG boosted its position in Evogene by 10.1% in the first quarter. UBS Group AG now owns 1,052,537 shares of the biotechnology company’s stock valued at $5,628,000 after buying an additional 96,527 shares during the last quarter. Bank of America Corp DE boosted its position in Evogene by 5.3% in the first quarter. Bank of America Corp DE now owns 841,552 shares of the biotechnology company’s stock valued at $4,500,000 after buying an additional 42,532 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in Evogene by 71.1% in the first quarter. Jane Street Group LLC now owns 50,129 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 20,837 shares during the last quarter. Hedge funds and other institutional investors own 29.88% of the company’s stock.

Shares of Evogene (EVGN) traded up 2.13% during midday trading on Thursday, reaching $5.27. 428 shares of the company traded hands. The stock’s market capitalization is $135.05 million. The stock’s 50-day moving average is $5.18 and its 200-day moving average is $5.20. Evogene has a 1-year low of $4.86 and a 1-year high of $7.09.

About Evogene

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.

Get a free copy of the Zacks research report on Evogene (EVGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evogene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.